These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10372838)

  • 41. [Medical-surgical integrated approach in the treatment of non-paraneoplasic hyperparathyroidism: our experience].
    Pulvirenti D; Aikaterini T; Campagna A; Ignaccolo L; Giustolisi N; Costa E
    Clin Ter; 2008; 159(5):307-10. PubMed ID: 18998031
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Involution of the parathyroid glands after renal transplantation.
    Lewin E
    Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):363-71. PubMed ID: 12815332
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism.
    Caravaca F; Cubero JJ; Jimenez F; López JM; Aparicio A; Cid MC; Pizarro JL; Liso J; Santos I
    Nephrol Dial Transplant; 1995; 10(5):665-70. PubMed ID: 7566580
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Natural course of secondary hyperparathyroidism after successful renal transplantation.
    Roof BS; Piel CF; Carpenter BJ; Gordan GS; Kountz S; Belzer F
    Proc Clin Dial Transplant Forum; 1971; 1():11-20. PubMed ID: 4951041
    [No Abstract]   [Full Text] [Related]  

  • 45. Vitamin D analogs: perspectives for treatment.
    Brown AJ; Slatopolsky E
    Miner Electrolyte Metab; 1999; 25(4-6):337-41. PubMed ID: 10681662
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Surgical treatment of the parathyroid gland in patients with end-stage renal disease.
    Albertucci M; Zielinski CM; Rothberg M; Sterpetti A; Klingman R; Ronk JF
    Surg Gynecol Obstet; 1988 Jul; 167(1):49-52. PubMed ID: 3381185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Treatment of secondary hyperparathyroidism in dialysis patients].
    Di Luca M
    G Ital Nefrol; 2009; 26 Suppl 49():S36-48. PubMed ID: 19941277
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A new experimental model for secondary hyperparathyroidism.
    Sancho JJ; Duh QY; Oms L; Sitges-Serra A; Hammond ME; Arnaud CD; Clark OH
    Surgery; 1989 Dec; 106(6):1002-8. PubMed ID: 2588105
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide.
    Mak RH; Turner C; Thompson T; Powell H; Haycock GB; Chantler C
    Br Med J (Clin Res Ed); 1985 Sep; 291(6496):623-7. PubMed ID: 3928054
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vitamin D and its analogs in chronic renal failure.
    Slatopolsky E; Brown AJ
    Osteoporos Int; 1997; 7 Suppl 3():S202-8. PubMed ID: 9536333
    [No Abstract]   [Full Text] [Related]  

  • 51. Medical treatment in primary and secondary hyperparathyroidism.
    Coburn JW; Brickman AS; Massry SG
    Semin Drug Treat; 1972; 2(1):117-35. PubMed ID: 4261783
    [No Abstract]   [Full Text] [Related]  

  • 52. Hyperparathyroidism in chronic renal failure.
    Papapoulos SE; Brownjohn AM; Junor BJ; Marsh FP; Goodwin FJ; Hately W; Lewin IG; Tomlinson S; Hendy GN; O'Riordan JL
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():59s-65s. PubMed ID: 606426
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Suppression of secondary hyperparathyroidism in uraemia: acute and chronic studies.
    Muirhead N; Catto GR; Edward N; Adami S; Manning RM; O'Riordan JL
    Br Med J (Clin Res Ed); 1984 Jan; 288(6412):177-9. PubMed ID: 6419845
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is control of secondary hyperparathyroidism optimal with the currently used calcium concentration in the CAPD fluid?
    Weinreich T; Rambausek M; Ritz E
    Nephrol Dial Transplant; 1991; 6(11):843-5. PubMed ID: 1775248
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Are we mismanaging calcium and phosphate metabolism in renal failure?
    Hsu CH
    Am J Kidney Dis; 1997 Apr; 29(4):641-9. PubMed ID: 9100059
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [New insights in the pathogenesis of secondary hyperparathyroidism].
    Cozzolino M; Butti A; Chiarelli G; Rocca-Rey L; Bellasi A; Galassi A; Gallieni M; Brancaccio D
    G Ital Nefrol; 2005; 22(4):329-36. PubMed ID: 16267793
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Calcium, phosphorus and vitamin D disorders in uremia.
    Slatopolsky E; Brown A; Dusso A
    Contrib Nephrol; 2005; 149():261-271. PubMed ID: 15876849
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism.
    Lee WT; Padayachi K; Collins JF; Cundy T
    J Am Soc Nephrol; 1994 Dec; 5(6):1344-8. PubMed ID: 7894000
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of secondary hyperparathyroidism in renal allograft recipients.
    Wilson RE; Hampers CL; Katz AI; Bernstein DS; Wachman A; Merrill JP; Murray JE
    Transplant Proc; 1969 Mar; 1(1):206-8. PubMed ID: 4944219
    [No Abstract]   [Full Text] [Related]  

  • 60. Management of hyperphosphatemia in patients with renal failure.
    Ghazali A; Ben Hamida F; Bouzernidj M; el Esper N; Westeel PF; Fournier A
    Curr Opin Nephrol Hypertens; 1993 Jul; 2(4):566-79. PubMed ID: 7859019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.